COVID-MSK: The Bodily Complaints Barometer: The Impact of the Corona Measures and of Contracting a COVID-19 Infection on the Body.

Sponsor
University Ghent (Other)
Overall Status
Completed
CT.gov ID
NCT05638685
Collaborator
(none)
490
1
1.8
276.2

Study Details

Study Description

Brief Summary

Since December 2019, a new corona virus (SARS-CoV-2) causing COVID-19 disease, has expeditiously spread over the entire globe. Almost a half billion people caught the disease, and in those who survived, it soon became clear that residual complaints are not rare phenomena. Early focus lay on diminished lung capacity and cardiovascular-related problems. As time passed however, it became more apparent that those are not the only residual symptoms survivors may experience.

Furthermore, nearly every country in the world took some sort of lockdown measures in order to try contain the spreading of the virus. These measures had great impact on all inhabitants, infected with the virus or not.

This questionnaire-based study therefore aims to investigate (a) the effects of a COVID-19 infection on fatigue and/or musculoskeletal complaints, new or already existing, but also (b) the effects of lockdown measures on fatigue and/or musculoskeletal complaints, new or already existing, in people living, working or studying in Belgium during the pandemic.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaire

Detailed Description

Since the start of the COVID-19 pandemic, almost half a billion people worldwide were infected with the new coronavirus, SARS-CoV-2, causing COVID-19 disease. In Belgium, 3.6 million people, a third of the population, contracted the disease. More than 30.000 patients did not survive this condition.

Many of those who did survive, however, complained of residual symptoms, even long after their infection. Initially the most reported and investigated complaints were lung and respiratory issues, but as time progressed, it became clear these were not the only residual problems after infection. A great deal of ex-patients reported lasting fatigue and musculoskeletal complaints, both myalgia and arthralgia, after they were deemed 'cured' and therefore discharged from the hospital. Since these complaints only became apparent when patients tried to resume their daily life outside the hospital, condsiderably less attention was given to these symptoms by clinicians and researchers. Therefore, this research aims to investigate the effects of a COVID-19 infection on fatigue and/or musculoskeletal complaints, both new or already existing.

In Belgium, as in many other countries all over the world, lockdown measures were installed to contain the spread of the virus. For certain periods, this meant an obligation to work from home and moreover, to only leave home for vital reasons. Before the pandemic, "telework" was rather exceptional; in a survey from September 2019, only 22% of respondents worked from home, and for just 1 day a week. So for many employees, this meant a hard transition from a fully ergonomic work space to an unadapted home environment. For those who used to walk or bike to work, physical activity levels dropped. Even more so since all sports and recreational facilities were ordered to close. Regardless of having to live through a COVID-19 infection, all these measures were of great impact on the population, and on their levels of physical activity. A second aim of this resaerch is thus to investigate the effect of lockdown measures on fatigue and/or musculoskeletal complaints, both new or already existing, in people living, working or studying in Belgium during these measures.

Study Design

Study Type:
Observational
Actual Enrollment :
490 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
The Bodily Complaints Barometer: A Survey to Investigate the Impact of the Corona Measures and of Contracting a COVID-19 Infection on the Body.
Actual Study Start Date :
Dec 22, 2021
Actual Primary Completion Date :
Feb 14, 2022
Actual Study Completion Date :
Feb 14, 2022

Arms and Interventions

Arm Intervention/Treatment
Dutch-speaking people living or working in Belgium

Every participant was asked to complete a questionnaire about the impact of a COVID-19 infection and/or the impact of lockdown measures as a result of the COVID-19 pandemic on fatigue and musculoskeletal complaints.

Other: Questionnaire
The questionnaire comprises demographics, job or school related questions, screen work questions, the International Physical Activity Questionnaire (IPAQ) and questions about the participant's health.

Outcome Measures

Primary Outcome Measures

  1. Musculoskeletal complaints following a COVID-19 infection, through the International Physical Activities Questionnaire (IPAQ). [3 months]

  2. Fatigue following a COVID-19 infection, through the Checklist Individual Strength (CIS). [3 months]

  3. Musculoskeletal complaints caused by lockdown measures, through the IPAQ and the Short Inventory to Monitor Psychosocial Hazards. [3 months]

    No prior COVID-19 infection

  4. Fatigue caused by lockdown measures, through the CIS and the Short Inventory to Monitor Psychosocial Hazards. [3 months]

    No prior COVID-19 infection

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Being at least 18 years old

  • Living and/or working in Belgium

  • Dutch speaking

Exclusion Criteria:
  • Being younger than 18 years of age

  • Not working or living in Belgium during the pandemic and lockdown measures

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ghent University, vakgroep revalidatiewetenschappen Ghent Oost-Vlaanderen Belgium 9000

Sponsors and Collaborators

  • University Ghent

Investigators

  • Study Director: Jessica Van Oosterwijck, Prof, Ghent University, Pain in Motion

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
University Ghent
ClinicalTrials.gov Identifier:
NCT05638685
Other Study ID Numbers:
  • B6702021000576
First Posted:
Dec 6, 2022
Last Update Posted:
Dec 6, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Ghent
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 6, 2022